secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-059147
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute Q3 FY2023 net loss $15.7M; cash $129.2M; Phase 3 for RZ358 on track for Q3 2023
--------------------------------------------------------------------------------

- Net loss of $15.7M for Q3 FY2023, compared to $11.2M in same period last year.
- Cash and equivalents $33.7M plus marketable debt securities $95.5M as of March 31, 2023.
- R&D expenses rose to $14.2M from $8.7M, driven by clinical trial and manufacturing costs.
- Company expects to commence Phase 3 study for RZ358 in Q3 calendar 2023; Phase 2 for RZ402 enrolling.
- G&A expenses increased to $2.9M from $2.1M due to higher personnel and stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923059147/0001104659-23-059147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923059147/tm2315328d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer